TABLE 1.
Characteristics of patients with SALI.
| Variables | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| Non-aspirin | Aspirin | P value | Non-aspirin | Aspirin | P value | |
| Patients number | 447 | 210 | 148 | 148 | ||
| Demographics | ||||||
| Age | 69.2 (56.8, 81.4) | 73.1 (64.1, 81.5) | 0.002 | 75.1 (58.7, 83.6) | 72.2 (62.6, 80.0) | 0.389 |
| Gender, male | 248 (55.5) | 145 (69.1) | <0.001 | 91 (61.5) | 94 (63.5) | 0.719 |
| Race | 0.127 | 0.870 | ||||
| Other/Unknown | 130 (29.1) | 58 (27.6) | 47 (31.76) | 43 (29.05) | ||
| Black | 48 (10.7) | 13 (6.2) | 9 (6.08) | 10 (6.76) | ||
| White | 269 (60.2) | 139 (66.2) | 92 (62.16) | 95 (64.19) | ||
| Vital/Laboratory variables | ||||||
| Temperature | 37.3 (37.0, 38.1) | 37.3 (37.0, 38.0) | 0.962 | 37.3 (37.0, 38.0) | 37.4 (37.0, 38.1) | 0.362 |
| Heart rate, bmp | 117.0 (100.0, 132.0) | 108.0 (94.3, 124.0) | <0.001 | 113.4 ± 21.9 | 112.3 ± 21.5 | 0.655 |
| Respiratory Rate | 30.0 (26.0, 35.0) | 28.0 (25.0, 34.0) | 0.025 | 29.8 (26.0, 34.0) | 28.0 (25.0, 34.3) | 0.607 |
| MBP, mmHg | 55.0 (47.0, 62.0) | 56.0 (47.3, 62.0) | 0.781 | 55.0 (48.8, 61.3) | 56.0 (47.8, 62.0) | 0.729 |
| SpO2 | 92.0 (88.0, 94.0) | 92.0 (89.3, 94.0) | 0.237 | 92.0 (89.0, 94.0) | 92.0 (89.0, 94.0) | 0.573 |
| WBC | 16.7 (10.4, 25.4) | 16.8 (10.7, 22.8) | 0.876 | 15.5 (10.3, 24.1) | 16.8 (10.0, 23.0) | 0.590 |
| Platelets | 115.0 (63.0, 176.0) | 133.0 (83.3, 191.5) | 0.003 | 135.5 (82.8, 192.8) | 131.5 (81.0, 192.5) | 0.782 |
| Hemoglobin | 9.5 (7.7, 11.1) | 9.4 (7.7, 11.4) | 0.601 | 9.7 (8.0, 11.4) | 9.2 (7.7, 11.3) | 0.322 |
| Lymphocytes count | 0.8 (0.4, 1.3) | 0.8 (0.5, 1.4) | 0.161 | 0.8 (0.5, 1.1) | 0.9 (0.6, 1.3) | 0.123 |
| Monocytes count | 0.6 (0.3, 1.1) | 0.8 (0.4, 1.2) | 0.003 | 0.6 (0.3, 1.1) | 0.8 (0.4, 1.3) | 0.046 |
| Neutrophils count | 11.9 (7.1, 18.9) | 11.6 (7.7, 18.0) | 0.691 | 11.7 (7.3, 18.5) | 12.4 (7.5, 17.8) | 0.600 |
| INR | 2.1 (1.8, 2.8) | 1.9 (1.7, 2.7) | 0.121 | 2.1 (1.8, 2.6) | 1.9 (1.7, 2.8) | 0.399 |
| Total bilirubin | 3.7 (2.6, 6.1) | 3.4 (2.5, 4.7) | 0.009 | 3.4 (2.6, 4.7) | 3.5 (2.7, 5.0) | 0.756 |
| Albumin | 2.71 ± 0.63 | 2.88 ± 0.56 | <0.001 | 2.88 ± 0.62 | 2.84 ± 0.54 | 0.608 |
| ALT | 119.0 (41.0, 367.0) | 118.5 (37.3, 289.8) | 0.446 | 115.5 (40.0, 390.0) | 121.5 (33.5, 296.8) | 0.639 |
| ALP | 168.0 (91.5, 295.5) | 126.5 (74.3, 250.8) | 0.002 | 165.0 (92.5, 238.0) | 141.0 (76.8, 261.8) | 0.310 |
| AST | 172.0 (66.5, 577.0) | 175.5 (78.5, 421.3) | 0.829 | 181.0 (57.0, 610.8) | 176.0 (80.0, 472.3) | 0.917 |
| CCI score | 5.0 (3.0, 8.0) | 6.0 (4.0, 8.0) | <0.001 | 6.0 (3.0, 8.0) | 6.0 (4.0, 8.0) | 0.601 |
| SOFA score | 9.0 (6.0, 12.5) | 9.0 (7.0, 12.0) | 0.532 | 9.0 (5.8, 12.0) | 9.0 (7.0, 11.3) | 0.690 |
| SAPS II score | 49.0 (39.0, 63.0) | 47.5 (37.3, 58.8) | 0.151 | 47.0 (36.8, 57.0) | 47.0 (37.8, 58.0) | 0.749 |
| Comorbidity | ||||||
| Hypertension | 89 (20.0) | 65 (31.0) | 0.002 | 38 (25.7) | 45 (30.4) | 0.365 |
| CAD | 50 (11.2) | 104 (49.5) | <0.001 | 49 (33.1) | 47 (31.8) | 0.804 |
| Cerebrovascular | 27 (6.0) | 32 (15.2) | <0.001 | 19 (12.8) | 21 (14.2) | 0.734 |
| Diabetes | 116 (26.0) | 77 (36.7) | 0.005 | 50 (33.8) | 48 (32.4) | 0.805 |
| AKI | 294 (65.8) | 162 (77.1) | 0.003 | 105 (71.0) | 109 (73.7) | 0.603 |
| Critical treatments on the first day | ||||||
| RRT | 43 (9.62) | 15 (7.14) | 0.297 | 16 (10.8) | 12 (8.1) | 0.427 |
| Vasopressor | 228 (51.01) | 110 (52.38) | 0.742 | 72 (48.7) | 75 (50.7) | 0.727 |
| Mechanical ventilation | 199 (44.52) | 105 (50.00) | 0.189 | 60 (40.5) | 76 (51.4) | 0.062 |
SALI: Sepsis-associated liver injury; MBP: mean blood pressure; SpO2: oxygen saturation; WBC: white blood cell; SOFA: sequential organ failure assessment; SAPS II: Simplified Acute Physiology Score II; INR: international normalized ratio; ALT: alanine aminotransferase; ALP: alkaline phosphatase; AST: aspartate aminotransferase; CCI: charlson comorbidity index; CAD: coronary artery disease; AKI: acute kidney injury; RRT: renal replacement therapy; PSM: Propensity Score Matching. P value <0.05 is considered statistical significance.